Search research articles
Contact Us
Filters
Showing results (71-80 of 115) with videos related to
Page
of 12
Sort By:
Clinical Lymphoma, Myeloma & Leukemia
|
December 12, 2018
Comparison of Peripheral Blast Clearance and Day 14 Bone Marrow Biopsy in Predicting Remission Status and Survival After 7+3 Induction in Acute Myeloid Leukemia
Fahrettin Covut, Divya Gupta, Raisa Pinto, et al.
Frontiers in Immunology
|
October 29, 2021
Prophylactic Tocilizumab Prior to Anti-CD19 CAR-T Cell Therapy for Non-Hodgkin Lymphoma
Paolo F Caimi, Gabriela Pacheco Sanchez, Ashish Sharma, et al.
Blood
|
November 19, 2020
Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma
Mehdi Hamadani, John Radford, Carmelo Carlo-Stella, et al.
The Lancet. Haematology
|
May 28, 2021
Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study
Mehdi Hamadani, Graham P Collins, Paolo F Caimi, et al.
Blood Advances
|
July 5, 2022
Loncastuximab tesirine in relapsed/refractory high-grade B-cell lymphoma: a subgroup analysis from the LOTIS-2 study
Juan P Alderuccio, Weiyun Z Ai, John Radford, et al.
American Journal of Hematology
|
March 25, 2024
BEAM versus pharmacokinetics-directed BuCyVP16 conditioning for patients with peripheral T-cell lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation
Robert Stuver, Agrima Mian, Samantha Brown, et al.
JAMA Oncology
|
September 1, 2022
Assessment of Pretreatment and Posttreatment Evolution of Neurofilament Light Chain Levels in Patients Who Develop Immune Effector Cell-Associated Neurotoxicity Syndrome
Omar H Butt, Alice Y Zhou, Paolo F Caimi, et al.
The Lancet. Oncology
|
May 14, 2021
Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial
Paolo F Caimi, Weiyun Ai, Juan Pablo Alderuccio, et al.
Blood Advances
|
October 23, 2023
Clinical outcomes of older and younger patients treated with loncastuximab tesirine in the LOTIS-2 clinical trial
Mehdi Hamadani, Alexander Spira, Xiaolei Zhou, et al.
Transplantation and Cellular Therapy
|
April 8, 2021
Physical Activity and Sleep Measures Using a Fitness Tracking Device during Hematopoietic Cell Transplantation: A Pilot Study
Najla El Jurdi, Nora Nock, Pingfu Fu, et al.
Page
of 12
Search research articles
Search
Showing results (71-80 of 115) with videos related to
Sort By:
Page
of 12
Clinical Lymphoma, Myeloma & Leukemia
|
December 12, 2018
Comparison of Peripheral Blast Clearance and Day 14 Bone Marrow Biopsy in Predicting Remission Status and Survival After 7+3 Induction in Acute Myeloid Leukemia
Fahrettin Covut, Divya Gupta, Raisa Pinto, et al.
Frontiers in Immunology
|
October 29, 2021
Prophylactic Tocilizumab Prior to Anti-CD19 CAR-T Cell Therapy for Non-Hodgkin Lymphoma
Paolo F Caimi, Gabriela Pacheco Sanchez, Ashish Sharma, et al.
Blood
|
November 19, 2020
Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma
Mehdi Hamadani, John Radford, Carmelo Carlo-Stella, et al.
The Lancet. Haematology
|
May 28, 2021
Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study
Mehdi Hamadani, Graham P Collins, Paolo F Caimi, et al.
Blood Advances
|
July 5, 2022
Loncastuximab tesirine in relapsed/refractory high-grade B-cell lymphoma: a subgroup analysis from the LOTIS-2 study
Juan P Alderuccio, Weiyun Z Ai, John Radford, et al.
American Journal of Hematology
|
March 25, 2024
BEAM versus pharmacokinetics-directed BuCyVP16 conditioning for patients with peripheral T-cell lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation
Robert Stuver, Agrima Mian, Samantha Brown, et al.
JAMA Oncology
|
September 1, 2022
Assessment of Pretreatment and Posttreatment Evolution of Neurofilament Light Chain Levels in Patients Who Develop Immune Effector Cell-Associated Neurotoxicity Syndrome
Omar H Butt, Alice Y Zhou, Paolo F Caimi, et al.
The Lancet. Oncology
|
May 14, 2021
Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial
Paolo F Caimi, Weiyun Ai, Juan Pablo Alderuccio, et al.
Blood Advances
|
October 23, 2023
Clinical outcomes of older and younger patients treated with loncastuximab tesirine in the LOTIS-2 clinical trial
Mehdi Hamadani, Alexander Spira, Xiaolei Zhou, et al.
Transplantation and Cellular Therapy
|
April 8, 2021
Physical Activity and Sleep Measures Using a Fitness Tracking Device during Hematopoietic Cell Transplantation: A Pilot Study
Najla El Jurdi, Nora Nock, Pingfu Fu, et al.
Page
of 12